Navigation Links
Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine

- Article Discussing Pharmacokinetics and Dose Proportionality of Company's Once-Daily Tramadol to be Published in Biopharmaceutics Journal -

LAVAL, QC, June 29, 2007 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that it will present a poster discussing the dose titration of its once-daily formulation of tramadol at the 3rd International Forum on Pain Medicine to be held June 28 to July 1, 2007 in Montreal, Canada.

The poster compares two different titration schedules for Labopharm's once-daily formulation of tramadol in three Phase III clinical trials: a six-day titration to a 300 mg dose (clinical trials MDT3-002 and MDT3-003) and a nine-day titration to a 300 mg dose (clinical trial MDT3-005). The comparison showed that percentage of adverse events and discontinuations due to adverse events was similar regardless of the titration schedule.

These results, in addition to the fact that Labopharm's once-daily tramadol formulation achieves steady state plasma levels after two days, suggest that a shorter titration schedule may be adequate for most patients. A previous study showed that most patients achieve pain control using Labopharm's once-daily tramadol at a dose of 200 mg. The data in this poster suggest that, for most patients, after starting with a dose of 100 mg for two days, the therapeutic dose of 200 mg could be achieved after two days without increased risk of side effects. If a patient requires a higher dose (300 mg), the therapeutic dose could be achieved after six days of titration (100 mg for 2 days; 200 mg for 3 days then 300 mg on the 6th day) without increased risk of side effects.

"The results of the comparison of titration periods reviewed in the poster suggest that patients may benefit from rapid titration to optimal analgesia without increased risk of side effects using our product," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm
'"/>




Page: 1 2 3

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Roche under the trade name of ... the world. In Feb.26, 2010, it was approved by ... available in China all come ...
(Date:8/28/2015)... DRAPER, Utah , Aug. 28, 2015  Today, ... and Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts ... CDC has found that contact lens wearers who do ... the greatest risk for eye infections. ... cleaning their lenses, but a clean lens case is ...
(Date:8/28/2015)... 2015 Research and ... the "Investigation Report on China,s Insulin Aspart ... Developed by Novo Nordisk, insulin aspart (under ... drug for the treatment of diabetes. Compared with ... insulin analog, starts working fast and reports higher ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... study shows that loss of Arf gene in ... the growth-enhancing environment of the bone,marrow, helping cells ... MEMPHIS, Tenn., Aug. 29 Results of a ... provide strong,evidence for why the drug imatinib (Gleevec(TM)), ...
... Aug. 29 Accera, Inc. announced today,that recent data ... Ketasyn(TM),(AC- 1202) in age-associated memory impairment (AAMI) showed that ... in older adults. AAMI is the decline in ... National Institute of Mental Health criteria for AAMI include,complaints ...
Cached Medicine Technology:St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia 2Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study 2Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study 3
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of furthering ... the second year to the Adams County Fairgrounds in Mendon, IL on May 30th, ... money to support music education in the underfunded school districts of Mendon and its ...
(Date:8/28/2015)... ... , ... As reported by Medical Daily on August 22 , Cellfina, ... last for two years, the longest of any cellulite reduction system currently on the ... long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director of the ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... who might personally be struggling with chemical dependency, may be able to find ... Rehabilitation, a results-driven holistic treatment center for addiction located in Western Michigan. Focusing ...
(Date:8/28/2015)... ... 28, 2015 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices, recently released Visio Stencils for the following product ... Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... the Veterans Award, honoring military veterans leading in business. Mr. Troy Mizell, ... , The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Altima Updates NetZoomâ„¢ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoomâ„¢ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:MyGenetx Board Member Receives Veterans Award 2
... EXTON, Pa., Nov. 2 Kensey Nash Corporation,(Nasdaq: ... exclusively licensed U.S. patent,6,175,669, Optical Coherence Domain Reflectometry ... expand the intellectual,property portfolio related to its chronic ... with enhanced optical sensing capabilities,allowing it to sense ...
... 24%, Digital Revenue Up 30% ... a.m. Eastern Time, NASHUA, N.H., Nov. 2 iCAD, ... the early detection of cancer, today announced financial,results for the ... nine,months year to date for 2007. Third Quarter 2007 ...
... to get screened for each point scored, CENTENNIAL, ... to great lengths to show support for their favorite ... freezing temperatures, traveling,great distances for the big game. Now ... health by raising awareness of a deadly disease --,prostate ...
... while complying ... US applicable standards, FREDERICA, Del., Nov. 1 ... the pharmaceutical industry,as well as spacesuits for NASA, announced ... use in their DoverPac (R) Containment Solution,products. ArmorFlex (R) ...
... 1 HHS Secretary Mike,Leavitt signed a Memorandum ... Clement today to improve the health status of ... best practices, and innovative approaches to learning,opportunities., ... HHS, national,headquarters., The MOU, which continues the ...
... Inc. (Nasdaq:,IFLG), a leading technology provider of mobile ... release its financial results,for the Third Quarter ended ... the press release, President and Chief Executive Officer,David ... host a conference,call with the financial community at ...
Cached Medicine News:Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:iCAD Reports Third Quarter Results 2Health News:iCAD Reports Third Quarter Results 3Health News:iCAD Reports Third Quarter Results 4Health News:iCAD Reports Third Quarter Results 5Health News:iCAD Reports Third Quarter Results 6Health News:iCAD Reports Third Quarter Results 7Health News:iCAD Reports Third Quarter Results 8Health News:Professional Football Takes the Field to Tackle Prostate Cancer 2Health News:Professional Football Takes the Field to Tackle Prostate Cancer 3Health News:ILC Dover Launches Revolutionary ArmorFlex (R) Pharmaceutical Product Contact Film 2Health News:HHS Secretary Leavitt Signs Agreement With Canada to Improve Indigenous Health Care Delivery and Access 2Health News:InfoLogix to Report Third Quarter and Nine Month Financial Results on November 8, 2007 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Medicine Products: